Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia

Venetoclax (VEN) is now widely used in the treatment of acute myelogenous leukemia (AML) in elderly patients who are not eligible for intensive remission induction therapy. Prolonged myelosuppression, increased incidence of infection, and long duration of hospital stay were major concerns for VEN tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Aiba, Masayuki, Shigematsu, Akio, Suzuki, Toma, Miyagishima, Takuto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977697/
https://www.ncbi.nlm.nih.gov/pubmed/36646889
http://dx.doi.org/10.1007/s00277-023-05102-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977697/
https://www.ncbi.nlm.nih.gov/pubmed/36646889
http://dx.doi.org/10.1007/s00277-023-05102-y

Ejemplares similares